Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer

There is no standard therapy for relapsed small cell lung cancer (rSCLC). We evaluated the efficacy and toxicity of a new triplet consisting of irinotecan (100 mg/m 2 Days 1 and 15 q28), cisplatin (40 mg/m 2 Days 1 and 15 q28) and mitomycin (6 mg/m 2 d1 q28) administered to a maximum of 6 cycles in individuals with rSCLC that had relapsed following first line treatment. Partial remisions were observed in 35% and progression in 30% of patients. Progression free survival measured 4.5 months (95% CI 0.8–8.2) and overall survival was 7.8 months (95% CI 5.3–10.3). QoL showed improvement in activity symptoms and stabilization of physical symptoms. As IPM was a well‐tolerated regimen with activity in rSCLC, a phase III trial comparing this triplet with other regimens in this setting is warranted.